Search PubMedSearch

PubMed · 8767549

[Dysmenorrhea].

Abstract

Primary dysmenorrhea is very frequent in ovulating women; it can even become a disease. In some cases, but not always, it is preceded by premenstrual tensions. Secondary dysmenorrhoea should be clearly differentiated, because it is a symptom of uterine abnormalities or adnexal diseases, whereas primary dysmenorrhoea is an entity in itself. The most frequent cause of secondary dysmenorrhoea is endometriosis. Dysmenorrhea membranacea is a rare event, but should not be forgotten. Primary dysmenorrhea involves the entire organism and the psyche of the suffering woman. The problem is its cyclic repetition and everlasting painful expectation. The pathogenesis is more clarified now but nevertheless not yet completely investigated. There is evidence that under the dominating role of sexual hormones paracrine sequelae are occurring, which result in a local increase of prostaglandins. The most important factor is the rhythmic ischemic reaction due to vasoconstriction in small arteries of the uterine wall, causing excruciating pains at times. The treatment is different whether or not children are immediately desired. Oral contraception and progestogens are useful when given days before the onset of menstruation. If the ovulatory cycle should be maintained, the drugs of choice are non-steroidal antiinflammatory preparations, among them naproxen and ibuprofen the most effective. Since those drugs exert side-effects when administered over a long period of time, alternatives must be available. The most appropriate ones are ASS, magnesium, calcium antagonists or tocolytic agents. Few new approaches to further alternative therapies (neuro-stimulation) could not provide a decrease of the uterine contractility in cases of primary dysmenorrhea.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Ludwig. 1996. [Dysmenorrhea].. https://pubmed.ncbi.nlm.nih.gov/8767549/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Microporous membrane drug delivery system for indomethacin.

Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of rheumatoid arthritis for more than a decade. The high incidence and severity of side effects, which are dose-related and associated with long-term administration, have limited its use. This has led to the search for new delivery systems which can overcome the side effects by controlling the drug release. In this study, Indomethacin Extended Release Formulation was developed by pelletization using the method of extrusion/spheronization. The drug containing pellets were further coated to achieve the required release profile as per USP. Coating systems developed on the principle of microporous membrane drug delivery using soluble salt gave the best results.

Anti-Inflammatory Agents, Non-Steroidal

Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study.

OBJECTIVE: To determine whether an educational package could influence the management of menorrhagia, increase the appropriateness of choice of non-hormonal treatment, and reduce referral rates from primary to secondary care. DESIGN: Randomised controlled trial. SETTING: General practices in East Anglia. SUBJECTS: 100 practices (348 doctors) in primary care were recruited and randomised to intervention (54) and control (46). INTERVENTIONS: An educational package based on principles of "academic detailing" with independent academics was given in small practice based interactive groups with a visual presentation, a printed evidence based summary, a graphic management flow chart, and a follow up meeting at 6 months. OUTCOME MEASURES: All practices recorded consultation details, treatments offered, and outcomes for women with regular heavy menstrual loss (menorrhagia) over 1 year. RESULTS: 1001 consultation data sheets for menorrhagia were returned. There were significantly fewer referrals (20% v 29%; odds ratio 0. 64; 95% confidence interval 0.41 to 0.99) and a significantly higher use of tranexamic acid (odds ratio 2.38; 1.61 to 3.49) in the intervention group but no overall difference in norethisterone treatment compared with controls. There were more referrals when tranexamic acid was given with norethisterone than when it was given alone. Those practices reporting fewer than 10 cases showed the highest increase in prescribing of tranexamic acid. CONCLUSIONS: The educational package positively influenced referral for menorrhagia and treatment with appropriate non-hormonal drugs.

Anti-Inflammatory Agents, Non-Steroidal